IGFBP2 and interstitial lung disease: Of great interest, initial levels of IGFBP-2 above 105 ng/ml were associated with a poor patient’s outcome 2 years later (KCO < 70% predicted), suggesting that serum levels of IGFBP-2 might predict the evolution of SSc-ILD.